{"nctId":"NCT00093015","briefTitle":"Trial to Reduce Cardiovascular Events With AranespÂ® Therapy (TREAT)","startDateStruct":{"date":"2004-08-01","type":"ACTUAL"},"conditions":["Kidney Disease","Diabetes Mellitus","Anemia"],"count":4038,"armGroups":[{"label":"Active","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: darbepoetin alfa"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"darbepoetin alfa","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hemoglobin less than or equal to 11 g/dL\n* History of Chronic Kidney Disease\n* eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73 m2 and less than or equal to 60 mL/min/1.73 m2\n* Tsat (transferrin saturation) greater than 15%\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Erythropoietic protein use within 12 weeks of randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)","description":"Time from randomization to the first confirmed composite event. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"602","spread":null},{"groupId":"OG001","value":"632","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to All-cause Mortality or End Stage Renal Disease (ESRD)","description":"Time from randomization to first event of all-cause mortality or ESRD. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"618","spread":null},{"groupId":"OG001","value":"652","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to All-cause Mortality","description":"Time from randomization to all-cause mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"395","spread":null},{"groupId":"OG001","value":"412","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cardiovascular Mortality","description":"Time from randomization to cardiovascular (CV) mortality. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"259","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Myocardial Infarction","description":"Time from randomization to fatal or non-fatal myocardial infarction (MI). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cerebrovascular Accident","description":"Time from randomization to fatal or non-fatal cerebrovascular accident (CVA). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Congestive Heart Failure","description":"Time from randomization to fatal or non-fatal congestive heart failure(CHF). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"205","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to End Stage Renal Disease","description":"Time from randomization to end stage renal disease (ESRD). Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"338","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline","description":"GFR was estimated using the following MDRD formula: 186 x \\[Serum creatinine\\]\\^(-1.154) x \\[Age\\]\\^(-0.203) x \\[0.742 if subject is female\\] x \\[1.210 if subject is black\\]. Change from baseline in eGFR at week 49 for each treatment group are presented. The treatment effect of the rate of decline in eGFR per year was estimated using the mixed model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.89","spread":"10.60"},{"groupId":"OG001","value":"-1.30","spread":"10.81"}]}]}]},{"type":"SECONDARY","title":"Change in Patient Reported Fatigue Relative to Baseline at Week 25","description":"Change in patient reported fatigue measured by the Functional Assessment of Cancer Therapy (FACT) - Fatigue scale from baseline to week 25. Range and direction of scale: 0 = most fatigue; 52 = least fatigue","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"10.3"},{"groupId":"OG001","value":"4.2","spread":"10.5"}]}]}]},{"type":"SECONDARY","title":"Time to Hospitalization Due to Acute Myocardial Ischemia","description":"Time from randomization to hospitalization due to acute myocardial ischemia. Kaplan-Meier estimate of the median time was not estimable due to low proportion of participants experiencing at least one events, therefore participants experiencing at least one event were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1219,"n":2019},"commonTop":["Oedema peripheral","Fatigue","Hypertension","Pain in extremity","Dyspnoea"]}}}